DaVita delivered fourth quarter 2025 adjusted operating income of $586 million and adjusted EPS of $3.40, with full-year adjusted OI reaching $2.094 billion and EPS of $10.78, landing in the top half of guidance. Despite a 1.1% decline in U.S. dialysis treatment volume due to elevated mortality and a 5.9% rise in patient care costs, the company achieved its first profitable year in Integrated Kidney Care (IKC) with $22 million in operating income. The company repurchased nearly 13 million shares for $1.8 billion in 2025. For 2026, DaVita guided for adjusted OI of $2.085 billion to $2.235 billion (3.2% growth at midpoint) and adjusted EPS of $13.60 to $15.00, representing 33% growth at the midpoint, driven by share repurchases, lower interest expenses, and the elimination of Mozarc losses.
| Metric | Value | Change |
|---|---|---|
| Q4 Adjusted Operating Income | $586 million | N/A |
| FY 2025 Adjusted Operating Income | $2.094 billion | Top half of guidance range |
| Q4 Adjusted EPS | $3.40 | N/A |
| FY 2025 Adjusted EPS | $10.78 | Top half of guidance range |
| U.S. Dialysis Treatment Volume (FY 2025) | Decline 1.1% | Down year-over-year |
| Revenue Per Treatment (FY 2025) | $410 | +4.7% year-over-year |
| Patient Care Costs Per Treatment (FY 2025) | N/A | +5.9% year-over-year |
| IKC Operating Income (FY 2025) | $22 million | First profitable year |
| Free Cash Flow (FY 2025) | Just over $1 billion | N/A |
| Leverage Ratio | 3.26x | Midpoint of target range (3-3.5x) |
DaVita achieved a major milestone by reporting its first profitable year in Integrated Kidney Care (IKC) with $22 million in full-year 2025 operating income. This success, driven by better clinical outcomes and shared savings, validates the value-based care model. Management expects incremental growth of $20 million in IKC operating income in 2026, signaling a maturing but still growing revenue stream that diversifies the business away from pure fee-for-service dialysis.
Management is aggressively targeting volume growth through clinical excellence, specifically focusing on vaccination rates, GLP-1 adoption, and advanced dialysis technologies. They noted that vaccinated patients had a 27% lower risk of mortality, and new technologies could reduce mortality by 20%. This focus aims to reverse the current trend of elevated mortality and missed treatments, which are currently suppressing volume growth.
The company continues to prioritize shareholder returns, repurchasing nearly 13 million shares for $1.8 billion in 2025. With leverage at 3.26x (midpoint of target), DaVita has capacity for further buybacks, which is a primary driver of the 33% expected EPS growth in 2026. The partnership with Elara Caring represents a $200 million investment to expand home-based care and reduce hospitalizations.
Despite rising wages and supply costs, DaVita managed PCC per treatment growth to 5.9% for the year, near the top of revised expectations but below original guidance. The company continues to focus on efficiency and innovation to maintain sustainable U.S. dialysis margins while investing in growth areas like international expansion and IKC.
U.S. dialysis treatments declined by 1.1% in 2025, driven by elevated mortality rates. Management guided for flat volume in 2026 and admitted they are not assuming any improvement in non-flu mortality. This structural headwind limits top-line growth potential and relies heavily on clinical initiatives that have a lag time of 2+ years to show results.
The expiration of enhanced premium tax credits creates a $40 million headwind in 2026 and $70 million in 2027. While partially offset by the resolution of cyber incident impacts, this represents a persistent drag on revenue per treatment (RPT) growth, which is only forecasted to be 1-2% for the year.
After achieving profitability, the expected incremental operating income growth from IKC is slowing to $20 million annually, compared to improvements of $40-50 million in recent years. This deceleration suggests the 'easy' margin expansion has occurred and future growth will be more incremental or dependent on harder-to-achieve shared savings.
Patient care costs per treatment increased 5.9% year-over-year, driven by wages and health benefits. While management expects cost growth of 1.25-2.25% in 2026, the high inflationary environment in 2025 squeezed margins, highlighting the operational leverage risk in the core dialysis business.
Overall: Management displayed a disciplined and confident demeanor, emphasizing the alignment between clinical excellence and financial performance. They acknowledged headwinds like mortality and ACA changes but expressed strong conviction in their strategic initiatives and capital allocation.
Confidence: HIGH - Management provided specific guidance ranges exceeding long-term targets and highlighted early successes in IKC profitability. They were direct in addressing operational challenges and detailed in their financial assumptions.
Range of $2.085 billion to $2.235 billion, representing 3.2% growth at the midpoint. Assumes flat U.S. dialysis treatment volume and 1-2% RPT growth.
Range of $13.60 to $15.00, representing 33% growth at the midpoint. Driven by increased operating income, lower share count, and elimination of Mozarc losses.
Range of $1 billion to $1.25 billion.
Expected to represent approximately 20% of full year guidance, or about $430 million at the midpoint.
Hedging & Uncertainty: Management used specific numbers for guidance but employed temporal hedges regarding volume recovery, stating 'you have to assume that the things that we outlined... come to fruition' and noting a 'lag between all of the implementation clinically and the full effect.' They used 'we expect' frequently for financial metrics but shifted to 'we think' or 'we believe' when discussing clinical outcomes and mortality improvements, indicating less control over these variables.
We executed with discipline, met challenges head on and delivered on our commitments we set at the beginning of the year. - Javier Rodriguez, CEO
Our IKC patients are 35% more likely to start dialysis with a permanent vascular access, resulting in a better patient experience and costs that are 3x lower during the first 180 days of dialysis. - Javier Rodriguez, CEO
We're managing 2 near-term financial headwinds, continued pressure on treatment growth driven by elevated mortality and the revenue per treatment impact from the expiration of enhanced premium tax credits. - Javier Rodriguez, CEO
The reality is it is a clinical story... to get to that 2%, you have to assume that the things that we outlined in our prepared remarks come to fruition. - Javier Rodriguez, CEO
We're not expecting a high-margin business here. And so I think $20 million a year is a comfortable landing spot for us right now in terms of contribution to OI growth. - Joel Ackerman, CFO
Analyst Sentiment: Analysts were focused on the sustainability of volume growth and the specific drivers behind the IKC profitability. Questions from Kevin Fischbeck (Bank of America) and Justin Lake (Wolfe Research) probed the timeline for returning to 2% volume growth and the repeatability of IKC gains. There was skepticism about the speed of clinical improvements translating to financial results.
Management Responses: Management was transparent about the lag effects of clinical initiatives on mortality, stating it could take 2 years to see benefits and full effect by 2029. They provided detailed breakdowns of the ACA headwind and cyber incident offsets, demonstrating a strong command of the financial mechanics.
Volume & Mortality: Analysts asked about the path to 2% growth. Management clarified it is a 'clinical story' dependent on reducing mortality through vaccines and new tech, with a 2-year lag.
ACA & Reimbursement: Discussion on the $40M headwind from expiring tax credits. Management noted open enrollment was more resilient than expected but remains cautious on payment yields.
IKC Profitability: Analysts questioned the $20M growth target vs. historical $40-50M improvements. Management explained the business is maturing and $20M is a 'comfortable landing spot.'
Elara Caring Investment: Management framed the $200M investment as both a financial return and a strategic move to reduce hospitalizations/missed treatments.
DaVita presents a compelling value proposition driven by aggressive capital allocation and the maturation of its Integrated Kidney Care (IKC) segment. The 33% projected EPS growth for 2026 is robust, fueled by share buybacks (13M shares in 2025) and the elimination of Mozarc losses, providing a near-term catalyst. While the core U.S. dialysis business faces headwinds from declining volumes (-1.1%) and ACA reimbursement pressure, the company's shift towards value-based care is validated by IKC's first profitable year. The key risks are the structural decline in patient volumes due to elevated mortality and the potential for rising costs to outpace pricing. However, management's confidence in clinical interventions (vaccines, GLP-1s) to reverse mortality trends, combined with a strong balance sheet (3.26x leverage) for continued buybacks, supports a positive risk-reward profile. Investors should monitor treatment volume trends and the integration of the Elara Caring partnership as primary indicators of long-term strategy success.
The expiration of enhanced premium tax credits for ACA exchange plans is creating a reimbursement headwind for the healthcare sector, specifically impacting dialysis providers. DaVita quantified this impact at $40 million for 2026, rising to $70 million in 2027. This reflects a broader tightening of healthcare subsidies and highlights the vulnerability of healthcare providers to policy changes affecting patient insurance coverage and reimbursement rates.
There is a noted resilience in patient enrollment and insurance retention despite the removal of subsidies. Management observed that 'open enrollment performed better than forecasted' and that patients are 'sophisticated understanding their insurance needs,' suggesting that demand for essential healthcare services like dialysis remains inelastic even as financial barriers rise.
The adoption of GLP-1 drugs and advanced dialysis technologies (medium cutoff dialyzers) is emerging as a significant trend in kidney care. Management highlighted that GLP-1s can reduce mortality for dialysis patients, while new technologies show promise of reducing mortality by 20%. This indicates a shift towards more effective, albeit potentially more complex, treatment protocols that could improve long-term patient survival.